Infectious disease treatment market analysis
Technavio's report, the global infectious disease treatment market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. Anti-infective drugs can act via a host defense system or can directly target the causative agent.
Infectious disease treatment industry forecast
This report covers the present scenario and the growth prospects of the Global Infectious Disease Treatment market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include:
• Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials)
• Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals)
• Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs)
• Antiparasitic drugs
Infectious disease treatment based on regions
• Americas
• APAC
• EMEA
Infectious disease treatment market vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Pfizer
Infectious disease treatment market driver
• Launch of Direct Acting Antivirals
• For a full, detailed list, view our report
Infectious disease treatment market challenge
• Generic Erosion
• For a full, detailed list, view our report
Infectious disease treatment market trend
• The emergence of IFN-free Therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Application
08. Global Antibacterial Drugs Market
08.1 Introduction
08.2 Market Size and Forecast
08.3 Market Segmentation by Chemical Class
08.4 Market Segmentation by Drug Origin
09. Global Antifungal Drugs Market
09.1 Introduction
09.2 Market Size and Forecast
09.3 Market Segmentation by Chemical Class
09.4 Market Segmentation by Geography
09.4.1 Antifungal Drugs Market in the US
09.4.2 Antifungal Drugs Market in Europe
10. Global Antiviral Drugs Market
10.1 Introduction
10.2 Market Size and Forecast
10.3 Market Segmentation by Disease
10.4 Global Hepatitis C Drugs Market
10.4.1 Market Size and Forecast
10.4.2 Geographical Segmentation
10.5 Global Hepatitis B Drugs Market
10.5.1 Market Size and Forecast
10.6 Global HIV Drugs Market
10.6.1 Market Size and Forecast
11. Global Antiparasitic Drugs Market
11.1 Market Size and Forecast
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 Gilead Sciences
20.2.2 GlaxoSmithKline
20.2.3 Pfizer
20.2.4 F. Hoffmann-La Roche
20.2.5 Johnson & Johnson
20.2.6 Merck
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 F. Hoffmann La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Geographical Segmentation by Revenue 2013
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Gilead Sciences
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Geographical Segmentation by Revenue 2013
21.2.4 Recent Developments
21.2.5 SWOT Analysis
21.3 GlaxoSmithKline plc
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Johnson & Johnson
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation by Revenue 2013
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Geographical Segmentation by Revenue 2013
21.4.6 Business Strategy
21.4.7 Recent Developments
21.4.8 SWOT Analysis
21.5 Merck
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Sales by Geography
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series